Marina S. Lebedkina

Moscow, MOW, Russian Federation

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Predictive value of a severity-of-illness score for toxic epidermal necrolysis (SCORTEN) factors for in-hospital mortality in Stevens-Johnson syndrome/toxic epidermal necrolysis.

Predictive value of a severity-of-illness score for toxic epidermal necrolysis (SCORTEN) factors for in-hospital mortality in Stevens-Johnson syndrome/toxic epidermal necrolysis.

Journal: Frontiers in medicine

Published: October 29, 2025

Case Series: Combination of dupilumab and omalizumab as a way to reduce dupilumab-associated adverse events in severe atopic dermatitis.

Case Series: Combination of dupilumab and omalizumab as a way to reduce dupilumab-associated adverse events in severe atopic dermatitis.

Journal: Frontiers in allergy

Published: September 01, 2025

Chronic inducible urticaria - having more than one is common and clinically relevant.

Chronic inducible urticaria - having more than one is common and clinically relevant.

Journal: Frontiers in immunology

Published: March 18, 2025

Can Synthetic Data Allow for Smaller Sample Sizes in Chronic Urticaria Research?

Can Synthetic Data Allow for Smaller Sample Sizes in Chronic Urticaria Research?

Journal: Clinical and translational allergy

Published: March 04, 2025

Recurrent angioedema manifestation and treatment response in two patients from different families caring the myoferlin gene mutation: case series.

Recurrent angioedema manifestation and treatment response in two patients from different families caring the myoferlin gene mutation: case series.

Journal: Orphanet journal of rare diseases

Published: February 25, 2025

Sex matters in CSU: Women face greater burden and poorer urticaria control, especially in midlife-CURE insights.

Sex matters in CSU: Women face greater burden and poorer urticaria control, especially in midlife-CURE insights.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: February 06, 2025

Treatment of atopic dermatitis with upadacitinib: adcare single center experience.

Treatment of atopic dermatitis with upadacitinib: adcare single center experience.

Journal: Frontiers in medicine

Published: February 13, 2024

Efficacy of dupilumab in real practice in the treatment of severe forms of asthma and atopic dermatitis (comparative retrospective study)

Efficacy of dupilumab in real practice in the treatment of severe forms of asthma and atopic dermatitis (comparative retrospective study)

Journal: Terapevticheskii arkhiv

Published: September 29, 2023

Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period.

Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period.

Journal: Frontiers in immunology

Published: July 16, 2023

Use of a combination of the virus-neutralizing monoclonal antibodies casirivimab and imdevimab for mild to moderate COVID-19 in patients at high risk of progression: Results of the non-interventional observational study

Use of a combination of the virus-neutralizing monoclonal antibodies casirivimab and imdevimab for mild to moderate COVID-19 in patients at high risk of progression: Results of the non-interventional observational study

Journal: Terapevticheskii arkhiv

Published: June 29, 2023

Positive experience with TNF-α inhibitor in toxic epidermal necrolysis resistant to high-dose systemic corticosteroids.

Positive experience with TNF-α inhibitor in toxic epidermal necrolysis resistant to high-dose systemic corticosteroids.

Journal: Frontiers in medicine

Published: April 21, 2023

Pre-exposure prophylaxis of new COVID-19 coronavirus infection with tixagevimab/cilgavimab in adult Moscow patients with primary immunodeficiencies

Pre-exposure prophylaxis of new COVID-19 coronavirus infection with tixagevimab/cilgavimab in adult Moscow patients with primary immunodeficiencies

Journal: Terapevticheskii arkhiv

Published: February 24, 2023

Showing 1-12 of 15

Last Updated: 09/26/2026